Results 21 to 30 of about 87,105 (259)
Nortriptyline for Treatment-Resistant Depression [PDF]
The Journal of Clinical Psychiatry, 2003 Up to 30% of patients with major depression fail to respond to an antidepressant trial, with most taking a selective serotonin reuptake inhibitor (SSRI) as initial treatment. While the tricyclic antidepressants might be effective for SSRI nonresponders, they have been relegated to third- and fourth-line treatment.
Andrew A, Nierenberg +8 more
openaire +2 more sources
TREATMENT RESISTANT DEPRESSION
Psychiatry and Clinical Psychopharmacology, 2021 Although it is reported that 25% of depressive patients remain resistant to antidepressant treatments, treatment resistant depression (TRD) has not yet been defined clearly.
Olcay YAZICI
doaj
Rethinking treatment-resistant depression to quasi-tenacious depression
European Psychiatry, 2023 With almost one-third of patients with major depression not adequately responsive to treatments, the management of treatment-resistant depression (TRD) has continued to be challenging.
Shokouh Arjmand +2 more
doaj +1 more source
Treatment-resistant depression and its diagnosis and treatment
Sichuan jingshen weisheng, 2022 The aim of this study is to explore the diagnostic strategies and options for treatment-resistant depression （TRD）. Despite the well-established efficacy of antidepressants， 20%~30% of depressive patients in the clinic fail to respond or respond poorly ...
Hu Shaohua
doaj +1 more source
Antidepressant discontinuation in treatment resistant depression
Contemporary Clinical Trials Communications, 2019 Treatment-resistant depression (TRD) is a growing problem in psychiatric practice with some 15–20% of depressed patients becoming chronically depressed and perhaps as many as 40% in tertiary settings.
Ziad A. Ali +2 more
doaj +1 more source
Neuromodulation for treatment-resistant depression [PDF]
F1000 Medicine Reports, 2012 Treatment-resistant depression affects at least 1-3% of the US population. This article reviews the current state of focal neuromodulation therapies for treatment-resistant depression, focusing on those treatments published clinical data. These include transcranial magnetic stimulation, transcranial direct current stimulation, magnetic seizure therapy,
Holtzheimer, Paul E., Mayberg, Helen S.
openaire +2 more sources
Case Report: Use of Subcutaneous Midazolam During an Episode of Catatonia
Frontiers in Psychiatry, 2021 Midazolam is a benzodiazepine (BZD) mainly used in anesthetic induction due to its pharmacokinetic features. Its place in the therapeutic management of catatonia remains to be determined. Here we present the case of a 65-year-old man who presented with a
Valentin Raymond +5 more
doaj +1 more source
Suicidality in Treatment-Resistant Depression Patients
European Psychiatry, 2023 Introduction Depression and treatment-resistant depression (RD) are associated with suicidal behavior (SB) at a higher rate. Objectives 1) determination prevalence of RD in district outpatient psychiatric сlinics (i.e., dispensaries) and the socio ...
E. B. Lyubov, N. D. Semenova
doaj +1 more source
Cushing's syndrome and treatment-resistant depression
Indian Journal of Psychological Medicine, 2017 Lekhansh Shukla
doaj +4 more sources
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background Emerging evidence suggests that low‐frequency neural oscillations are dynamically regulated by consciousness levels, with the recovery of low cortical activity potentially serving as a neurophysiological substrate for conscious emergence. Targeted enhancement of these low‐frequency rhythms in patients with disorders of consciousness
Chuan Xu +10 more
wiley +1 more source